Equities researchers at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a "hold" rating on the biotechnology company's stock.
Separately, Northland Securities cut shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a research note on Friday, January 6th.
Get Nabriva Therapeutics alerts:Nabriva Therapeutics Stock Up 10.7 %
NBRV opened at $1.76 on Thursday. The firm's 50-day simple moving average is $1.81 and its 200-day simple moving average is $3.47. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.40 and a current ratio of 2.20. Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $13.50. The firm has a market cap of $53.93 million, a price-to-earnings ratio of -0.09 and a beta of 1.67.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last released its earnings results on Thursday, November 10th. The biotechnology company reported ($4.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.03) by ($0.18). The business had revenue of $9.15 million for the quarter, compared to analyst estimates of $10.68 million. Nabriva Therapeutics had a negative net margin of 133.25% and a negative return on equity of 120.02%. Equities research analysts anticipate that Nabriva Therapeutics will post -17.37 EPS for the current fiscal year.Institutional Inflows and Outflows
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC raised its holdings in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the period. Renaissance Technologies LLC owned about 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent quarter. 0.23% of the stock is currently owned by hedge funds and other institutional investors.
Nabriva Therapeutics Company Profile
(Get Rating)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Read More
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.